Clinical Trial Update: A Dose Escalation Study of IBI333 in Subjects With Neovascular Age-related Macular Degeneration [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation study of IBI333 in neovascular age-related macular degeneration has completed enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• IBI333

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Neovascular Age-related Macular Degeneration | Phase 1 | Status: COMPLETED